2024-04-27

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting​

2024-04-08

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting​

2023-08-02

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting​

2023-05-05

Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary

2023-02-28

Arbele has entered a joint venture with the Chinese Manufacturers’ Association of Hong Kong (CMA) with a vision to establish accredited cell banking facilities in Hong Kong and Greater Bay Areas

2023-02-09

The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer

2022-10-24

Arbele CEO Dr. John Luk, attended and presented at the Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship in Washington DC, USA

2022-09-28

嘉立醫療科技於2022年港澳台創新創業大賽榮獲二等獎 / Caleb won 2nd prize at Hong Kong, Macao and Taiwan Innovation and Entrepreneurship Competition 2022

2022-08-10

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers​

2022-04-11

Arbele has been Inducted in the Hong Kong Tech 300 Angel Fund Program